The Children’s Hospital at Montefiore (CHAM) is bringing the medical miracle of pediatric heart transplantation to the Bronx, following the recent approval of its transplant center application by the New York State Department of Health. This important approval clears the way for specialists at CHAM, recently ranked among America’s top children’s hospitals, to treat any congenital or acquired heart abnormality in children and adolescents.

Intervention Triage strategY study, published in the September 2, 2008 issue of the Journal of American College of Cardiology, shows that Angiomax® (bivalirudin) monotherapy provides moderate- and high-risk (unstable angina (UA)/non - ST elevation myocardial infarction) acute coronary

Millennium: The Takeda Oncology Company announced the publication of results from the 682 patient, randomized, Phase III VISTA(1) trial in this week’s edition of the New England Journal of Medicine. The results showed a significant survival benefit and a 30 percent complete remission (CR) rate with VELCADE, melphalan and prednisone (VcMP) compared to 4 percent for melaphalan and prednisone (MP) alone in previously untreated multiple myeloma patients.

BIOTRONIK announced the enrollment of the first patient into the EchoCRT (Echocardiography guided Cardiac Resynchronization Therapy) study. Drs William T. Abraham and Ralph Augostini at The Ohio State University Medical Center in Columbus, Ohio, USA, enrolled and implanted the Lumax HF-T CRT-D device in the first patients in EchoCRT.

Biotechnology company Arana Therapeutics Limited (ASX: AAH) announced that it has completed recruitment in its Phase II dose-ranging psoriasis study for its anti-inflammatory drug ART621. Completion of recruitment means that formal results of the study should be available in early 2009. Arana also confirmed that it is planning to submit an Investigational New Drug (IND) application for ART621 in the rheumatoid arthritis indication in the fourth quarter of 2008.

Do you want to hear more about the impact of recent reforms on dentists, dental care professionals and patients? A conference exploring changes in regulation affecting dentistry will be taking place on 9 October 2008 at Woburn House in London.

TomoTherapy Incorporated (NASDAQ: TOMO) announced that it has received FDA 510(k) clearance for its TomoDirect™ radiation therapy technology. TomoDirect is an innovative new discrete-angle, sliding-beam delivery mode for the Hi•Art® treatment system.

Scientists at the National Cancer Institute in the US say more research is needed into the effects of low-dose radiation on cardiovascular risk, an area that remains controversial and about which there is too much uncertainty to give reliable estimates of numbers affected, compared to the well documented risks of cancer from radiation exposure.

Protherics PLC (”Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces the initiation of a phase 2a proof-of-concept study of Prolarix™, a targeted prodrug chemotherapy being developed for the treatment of primary liver cancer (hepatocellular carcinoma or “HCC”).

The angiotensin-receptor blocker (ARB) telmisartan should be regarded as a potential treatment for vascular disease or high-risk diabetes, in the 20% of patients who are unable to tolerate the standard treatment of angiotensin-converting enzyme (ACE) inhibitors.